G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Other Long-Term Assets
â‚ą110.3m
CAGR 3-Years
101%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Long-Term Assets
â‚ą12B
CAGR 3-Years
3%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Long-Term Assets
â‚ą8.3B
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
19%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Long-Term Assets
â‚ą46.8B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
13%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Long-Term Assets
â‚ą6.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
15%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Long-Term Assets
â‚ą1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Other Long-Term Assets?
Other Long-Term Assets
110.3m INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Other Long-Term Assets amounts to 110.3m INR.

What is Glenmark Life Sciences Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
7%

Over the last year, the Other Long-Term Assets growth was 34%. The average annual Other Long-Term Assets growth rates for Glenmark Life Sciences Ltd have been 101% over the past three years , 7% over the past five years .

Back to Top